Eculizumab

USDailyMed:Eculizumab AU:B2 L04AJ01(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 219685-50-4 DB01257 none A3ULP0F556 D03940 ChEMBL1201828 Eculizumab, sold under the brand nameSolirisamong others, is a recombinanthumanized monoclonal antibodyused to treatparoxysmal nocturnal hemoglobinuria,atypical hemolytic uremic syndrome, generalizedmyasthenia gravis, andneuromyelitis optica.In people with paroxysmal nocturnal hemoglobinuria, it reduces both thedestruction of red blood cellsand need forblood transfusion, but does not appear to affect the risk of death.Eculizumab was the first medication approved for each of its uses, and its approval was granted based on small trials.It is given byintravenous infusion.It is a humanizedmonoclonal antibodyfunctioning as a terminalcomplementinhibitor.It binds to the complement C5 protein and inhibits activation of the complement system, a part of the body's immune system.This binding prevents the breakdown of red blood cells in the bloodstream (intravascular hemolysis) in people with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The most frequently reported adverse reactions for people with paroxysmal nocturnal hemoglobinuria include headache, nasopharyngitis (common cold), back pain and nauseaThe most frequently reported adverse reactions for people with atypical hemolytic uremic syndrome include headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, swelling of lower legs or hands, nausea, urinary tract infections and fever Eculizumab (Soliris) isdeveloped, manufactured, and marketed byAlexion Pharmaceuticals.